Pyrilinks cleared for US:
This article was originally published in Clinica
Executive Summary
Metra Biosystems' (US) Pyrilinks bone resorption tests have been cleared for US marketing by the FDA. The two urine-based assays (polyclonal and monoclonal) provide a quantitative measure of the excretion of pyridinium crosslinks as an indicator of type I collagen resorption. These assays join Alkphase-B, which measures serum levels of alkaline phosphatase, cleared in the US in August. Pyrilinks-D, which measures deoxypyridinoline, is pending FDA clearance.
You may also be interested in...
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics
CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.